Over 60 cases of haemangioma associated with thrombocytopenia have been reported since the original description of this syndrome by Kasabach and Merritt (1940) . The accumulation of isotopelabelled platelets (Kontras et al. 1963 ) and fibrinogen (Wacksman et al. 1966) within the tumour has confirmed intravascular coagulation as the cause of the associated coagulopathy.
Reduction in tumour size after treatment with corticosteroids in uncomplicated haemangiomata was reported by Fost and Esterly (1968) . Sustained improvement of haematological abnormalities in the Kasabach Merritt syndrome treated with steroids alone has not, however, been well documented.
Although surgical excision or local radiotherapy have been the most popular methods of treatment in the past (Esterly and Soloman, 1972) , Oski and Naimnan (1972) Katz and Askin, 1968; Schneider and Lascari 1968; Odievre et al., 1971) . It is uncertain whether in these cases the effect of steroid therapy is primarily on the haemangioma itself or on the associated coagulation defect. Corticosteroids have been shown by Zweifach, Shorr, and Black (1953) to have a direct influence on vascular tone and to sensitize vessels to the effect of vasoconstrictor amines. Thus resolution of the haemangioma may follow a reduction in its blood supply with a consequent reduction in local intravascular coagulation.
More attractive, however, is the hypothesis that the steroid enhances thrombosis and inhibits subsequent fibrinolysis within the vascular channels, thus leading to their obliteration. The effect of corticosteroids on coagulation and fibrinolytic mechanisms is complex. Ozsoylu, Strauss, and Diamond (1962) showed steroid therapy to be associated with increased activity of antihaemophilic globulin and a reduction in partial thromboplastin time. Hypercoagulability is a recognized problem in patients receiving treatment with steroids and thromboembolic complications occurring in such patients were reviewed by Cosgriff (1951) . Although steroids may enhance physiological fibrinolysis in vivo (Fearnley and Bunim, 1951) 'pathological' fibrinolysis was inhibited in patients with hepatic cirrhosis (Kwaan and McFadzean, 1956), and Isacson (1971) showed that prednisone diminished the content of plasminogen activator in the walls of superficial veins. In support of the latter hypothesis our own results show a fall in the plasma fibrinogen concentrations following immediately upon the initiation of treatment, and a rather slow recovery therafter. Furthermore, the raised concentrations of serum FDP in Case 2 rapidly returned to normal. The temporal relations between haematological and haemangioma responses do not suggest that the primary effect of treatment is upon haemangioma. They infer that the normal resolution of such haemangiomata may be dependent upon naturally occurring thrombosis within the vascular channels and that such spontaneous regression may be accelerated by prednisone therapy. If this is indeed the mechanism of response then investigation of the use of more potent inhibitors of fibrinolysis, such as E-amino caproic acid, might be of particular value.
Surgical extirpation or irradiation of haemangiomata as recommended previously will frequently be successful in resolving associated coagulation abnormalities. Nevertheless these treatments commonly leave residual scarring, and in the case of irradiation local necrosis with haemorrhage, and even later malignancy may be additional complications. Aggressive therapy with prednisone obviates these sequelae. It appears to have the virtue of precipitating a spontaneous type of resolution and should be considered as a first choice in the treatment of complicated haemangiomata.
